COACT Study: CGRPmAbs + OnabotulinumtoxinA Assessment of Chronic Migraine Treatments Study
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Chronic migraine patients treated with OnabotulinumtoxinA may experience breakthrough
headaches, especially toward the end of their 12-week therapy. The addition of a CGRPmAb
could help in decreasing or eliminating these episodes, but this combination is considered
"experimental" by many payers, which often leads to a denial of coverage. Currently, there is
no reference in the literature or data to support the treatment of chronic migraine with
OnabotulinumtoxinA and CGRPmAbs (Aimovig, Ajovy, Emgality or Vyepti) combination therapy.
This has resulted in many patients and providers having to settle for one or the other.
Investigators hopes to provide crucial data and findings to support the addition of CGRPmAb
in some chronic migraine patients currently on monotherapy OnabotulinumtoxinA.